-
Biogen's Aducanumab Fails To Win FDA Panel Backing
Friday, November 6, 2020 - 5:04pm | 451Read More...Biogen Inc (NASDAQ: BIIB) failed to win the backing of the FDA panel which reviewed the BLA for its controversial Alzheimer's drug aducanumab, an antibody which targets amyloid-beta. What Happened: FDA's Peripheral and Central Nervous System Drugs Advisory Committee met Friday to...
-
IBM, Pfizer Collaborate On Early Alzheimer's Detection With Artificial Intelligence
Friday, October 23, 2020 - 9:32am | 454Read More...International Business Machines Corp (NYSE: IBM) and Pfizer Inc (NYSE: PFE) published results in The Lancet eClinical Medicine on the early detection of Alzheimer’s Disease. What Happened: Researchers from the two companies designed artificial intelligence to detect...
-
AC Immune Surges Higher On Alzheimer's Trial Update
Thursday, July 16, 2020 - 9:57am | 376Read More...Shares of Swiss biopharma AC Immune SA (NASDAQ: ACIU) were advancing strongly Thursday following a clinical trial update from the company. What Happened: AC Immune announced positive interim tolerability and immunogenicity results from the initial dosing group in a Phase 1b/2a...
-
Why Nano-Cap Biotech Cassava Is Losing 75% Of Its Market Cap
Friday, May 15, 2020 - 11:35am | 391Read More...Cassava Sciences Inc (NASDAQ: SAVA) shares have tumbled to their lowest level since mid-December 2019 after the company issued an adverse clinical readout. Cassava's Phase 2 Results In Alzheimer's Austin, Texas-based Cassava released top-line results from a Phase 2 study of its...
-
Why Axsome Is Touching The $100 Level For The First Time In Months
Monday, April 27, 2020 - 9:33am | 368Read More...Axsome Therapeutics Inc (NASDAQ: AXSM), which was a high-flier for most of 2019, has come off the all-time highs reached late last year thanks to the COVID-19 pandemic and a negative readout in late March. Positive Phase 2/3 data released by the company Monday morning seems to have...
-
BioXcel Therapeutics CEO Says Wearable Devices Are Another Tool To Combat Alzheimer's Agitation
Wednesday, April 15, 2020 - 11:03am | 553Read More...BioXcel Therapeutics (NASDAQ: BTAI) founder and CEO Dr. Mehta Vimal spoke with Benzinga about its BXCL-501 drug candidate for agitation in Alzheimer's patients — and how it relates to wearable devices. The drug has been granted Fast Track Designation by the FDA. Benzinga:...
-
Eli Lilly Suffers Setback As Alzheimer's Study Fails To Meet Primary Endpoint
Monday, February 10, 2020 - 12:22pm | 358Read More...Eli Lilly And Co (NYSE: LLY) shares were losing ground Monday following an announcement concerning the result of a Phase 2/3 study of an experimental Alzheimer's drug. Lilly said an analysis performed by the Washington University School of Medicine on data from a Phase 2/3 study, the ...
-
Neurotrope Rips 150% Higher On Improved Alzheimer's Data, NIH Funding
Wednesday, January 22, 2020 - 11:14am | 329Read More...Shares of thinly-traded microcap biopharma Neurotrope Inc (NASDAQ: NTRP) gap-opened sharply higher on above 50 times average volume following a corporate update from the company. Detailed Analysis Shows Promise Following the completion of data analysis for a confirmatory Phase 2 study dubbed "...
-
Biogen's CTAD Presentation On Aducanumab Elicits Mixed Response
Thursday, December 5, 2019 - 2:01pm | 594Read More...Biogen Inc's (NASDAQ: BIIB) presentation of aducanumab data at the Clinical Trials On Alzheimer's Disease Congress has drawn a mixed response. In late October, Biogen announced plans to revive its Alzheimer's program following a new analysis conducted by the company in consultation...
-
Biotech Stock On The Radar: Anavex, A Neurology-Focused Precision Medicine Company
Wednesday, September 25, 2019 - 4:32pm | 1406Read More...The European Rett Syndrome Conference gets underway Friday in Finland. Among the presenters: a New York-based micro-cap biotech that has an investigational asset to treat Rett syndrome in its pipeline. Anavex Life Sciences Corp (NASDAQ: AVXL), founded in 2006, is a biotech that focuses...
-
Neurotrope's Approach To Alzheimer's Disease: 'Our Improvement Data Is The Best Anyone Has'
Sunday, August 11, 2019 - 3:20pm | 1061Read More...Dr. Daniel Alkon, the chief scientific officer at Neurotrope Inc (NASDAQ: NTRP), discussed the fight against Alzheimer's disease in an interview with Benzinga. Benzinga: What is bryostatin, and how is it used for the treatment in patients with moderate to severe Alzheimer's disease?...
-
Analysts Digest Biogen's Alzheimer's Disappointment: 'There Isn't Much To Be Excited About'
Friday, March 22, 2019 - 12:30pm | 595Read More...Biogen Inc (NASDAQ: BIIB) shares plunged nearly 30 percent Thursday after, along with development partner Eisai Co., Ltd (OTC: ESALY) announced the decision to scrap two late-stage trials evaluating their Alzheimer's candidate aducanumab. The Analysts Mizuho Securities analyst Salim Syed...
-
Eisai Launches Confirmatory Late-Stage Trial Of Second Alzheimer's Asset After Setback
Friday, March 22, 2019 - 8:55am | 479Read More...Undeterred by the failure of one of its Alzheimer's pipeline assets, Eisai Co., Ltd (OTC: ESALY) is stepping up efforts to further advance its clinical pipeline. Apart from aducanumab — for which trials were scrapped — the company has two more assets for Alzheimer...
-
Biogen Plunges 25% After Company Discontinues Alzheimer's Drug Study
Thursday, March 21, 2019 - 7:17am | 348Read More...Shares of neuroscience company Biogen Inc (NASDAQ: BIIB) lost more than 25 percent Thursday morning after the company said it will discontinue an ongoing Alzheimer's drug study. What Happened Biogen and its partner Japan-based Eisai said they will discontinue an ongoing global Phase 3...
-
A Tale Of 2 Biotechs: Axsome, Axovant Report Contrasting Outcomes For Neurologic Drugs
Monday, December 10, 2018 - 11:32am | 593Read More...Biotechs Axsome Therapeutics Inc (NASDAQ: AXSM) and Axovant Sciences Ltd (NASDAQ: AXON) were taking diverging paths Monday. While shares of Axsome surged higher by nearly 8 percent, Axovant shares were down by more than 25 percent at the time of publication. Positive Interim Results...
